抗肥胖药物疗效及安全性临床研究进展  

Clinical study progression on efficacy and safety of anti-obesity drugs

作　　者：尹仕红[1] Yin Shihong.(Department of Internal Medicine, Affiliated Hospital of Hubei Three Gorges Polytechnic College, Yichang 443000, Chin)

机构地区：[1]湖北三峡职业技术学院附属医院内科,宜昌443000

出　　处：《国际内分泌代谢杂志》2017年第3期168-171,共4页International Journal of Endocrinology and Metabolism

摘　　要：抗肥胖药物治疗是肥胖管理中的辅助治疗手段.很多曾被广泛应用的抗肥胖药物因其不良反应而受到限制.近年来一些抗肥胖新药陆续上市,如奥利司他、利拉鲁肽、绿卡色林、芬特明/托吡酯、纳曲酮/安非他酮等.研究显示,有些降糖药物如二甲双胍、普兰林肽也具有减重作用.其他抗肥胖药物还包括植物提取物等.对抗肥胖药物的疗效及安全性的了解,将为临床治疗肥胖提供有力的证据.The application of anti-obesity drugs is an adjunctive pharmacotherapy in the management of obesity.Many widely used anti-obesity drugs were limited for side effects.New anti-obesity drugs appear on the market continuously in recent years,such as orlistat,liraglutide,lorcaserin,fentermine/topiramate and naltrexone/bupropion.Some hypoglycemic drugs （such as metformin,pramlintide） also have effects of weight loss.Other anti-obesity drugs include plant extracts,etc.Understanding of the efficacy and safety of anti-obesity drugs will provide strong evidence for the clinical treatment of obesity.

关 键 词：抗肥胖药物 疗效 安全性 临床试验 

分 类 号：R589.2[医药卫生—内分泌]